Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 11/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.36 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.36 |
| ▸ | TK2 | O00142 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9892708 | 1.00 | TK1 (0.37) | TK1GRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL808082 | 0.87 | TK1 (0.51) | TK1TK2 | |
| SCHEMBL808083 | 0.87 | TK1 (0.51) | TK1TK2 | |
| SCHEMBL807914 | 0.86 | TK1 (0.37) | TK1GRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL9892722 | 0.86 | LMNA (0.38) | TK1GRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL9892723 | 0.86 | LMNA (0.38) | TK1GRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL807913 | 0.86 | TK1 (0.37) | TK1GRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL9891088 | 0.80 | TK1 (0.38) | TK1GRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL9891087 | 0.80 | TK1 (0.38) | TK1GRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL807972 | 0.78 | DUT (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142897-A1 | PHOSPHONATES SYNTHONS FOR THE SYNTHESIS OF PHOSPHONATES DERIVATIVES SHOWING BETTER BIOAVAILABILITY | UNIVERSITE D'ORLEANS (FR) | 2012-06-07 | — | — | US | disclosed |
| WO-2012034719-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-22 | — | — | WO | disclosed |
| EP-2270021-A1 | Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability | Centre National de la Recherche Scientifique (FR) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010146127-A1 | PHOSPHONATES SYNTHONS FOR THE SYNTHESIS OF PHOSPHONATES DERIVATIVES SHOWING BETTER BIOAVAILABILITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142897-A1 | PHOSPHONATES SYNTHONS FOR THE SYNTHESIS OF PHOSPHONATES DERIVATIVES SHOWING BETTER BIOAVAILABILITY | PNP, PHPT1, TYMP | TK1 75/4885GRIA1 3940/4885GRIA2 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.